Jupiter Endovascular Exits Stealth With $21M in New Financing to Fund Pivotal Trial for Pulmonary Embolism
Jupiter Endovascular, a medical technology startup, has exited stealth mode with $21 million in new financing to fund a pivotal trial for Pulmonary Embolism. The company is developing a new class of endovascular procedures using Endoportal Control™ technology, which aims to bring the precision of direct surgical access to catheter-based interventions. Carl J. St. Bernard has been appointed as CEO, bringing over 30 years of experience in the life sciences industry.
The funding round, led by Sonder Capital with participation from strategic investors, will support the upcoming pivotal trial and development of additional clinical applications. Jupiter's technology addresses limitations in catheter-based therapies by providing stability and control within complex cardiovascular anatomies, potentially revolutionizing treatment for millions of patients worldwide.
Jupiter Endovascular, una startup nel settore della tecnologia medica, è uscita dalla modalità stealth con 21 milioni di dollari di nuovi finanziamenti per finanziare uno studio clinico cruciale per l'embolia polmonare. L'azienda sta sviluppando una nuova classe di procedure endovascolari utilizzando la tecnologia Endoportal Control™, che mira a portare la precisione dell'accesso chirurgico diretto nelle interventi basati su cateteri. Carl J. St. Bernard è stato nominato CEO, portando oltre 30 anni di esperienza nel settore delle scienze della vita.
Il round di finanziamento, guidato da Sonder Capital con la partecipazione di investitori strategici, sosterrà il prossimo trial cruciale e lo sviluppo di ulteriori applicazioni cliniche. La tecnologia di Jupiter affronta le limitazioni delle terapie basate su cateteri fornendo stabilità e controllo all'interno di anatomie cardiovascolari complesse, potenzialmente rivoluzionando il trattamento per milioni di pazienti in tutto il mondo.
Jupiter Endovascular, una startup de tecnología médica, ha salido de la fase de sigilo con 21 millones de dólares en nueva financiación para apoyar un ensayo pivotal para la embolia pulmonar. La empresa está desarrollando una nueva clase de procedimientos endovasculares utilizando la tecnología Endoportal Control™, que busca llevar la precisión del acceso quirúrgico directo a intervenciones basadas en catéteres. Carl J. St. Bernard ha sido nombrado CEO, aportando más de 30 años de experiencia en la industria de ciencias de la vida.
La ronda de financiación, liderada por Sonder Capital con la participación de inversores estratégicos, apoyará el próximo ensayo pivotal y el desarrollo de aplicaciones clínicas adicionales. La tecnología de Jupiter aborda las limitaciones de las terapias basadas en catéteres proporcionando estabilidad y control dentro de anatomías cardiovasculares complejas, potencialmente revolucionando el tratamiento para millones de pacientes en todo el mundo.
Jupiter Endovascular는 의료 기술 스타트업으로, 2100만 달러의 새로운 자금을 확보하고 폐색전증에 대한 중요한 임상 시험을 지원하기 위해 은폐 모드에서 벗어났습니다. 이 회사는 Endoportal Control™ 기술을 사용하여 카테터 기반 개입에 대한 직접 수술 접근의 정밀성을 가져오는 새로운 유형의 혈관내 수술 절차를 개발하고 있습니다. Carl J. St. Bernard가 CEO로 임명되어 생명 과학 산업에서 30년 이상의 경험을 가지고 있습니다.
이 자금 조달 라운드는 전략적 투자자들의 참여로 Sonder Capital이 주도하며, 향후 중요한 임상 시험 및 추가 임상 응용 프로그램 개발을 지원할 것입니다. Jupiter의 기술은 복잡한 심혈관 해부학 내에서 안정성과 제어력을 제공하여 카테터 기반 치료의 한계를 해결하며, 전 세계 수백만 환자에 대한 치료를 혁신할 가능성이 있습니다.
Jupiter Endovascular, une startup en technologie médicale, a quitté le mode furtif avec 21 millions de dollars de nouveaux financements pour soutenir un essai crucial sur l'embolie pulmonaire. L'entreprise développe une nouvelle classe de procédures endovasculaires utilisant la technologie Endoportal Control™, qui vise à apporter la précision d'un accès chirurgical direct aux interventions par cathéter. Carl J. St. Bernard a été nommé PDG, apportant plus de 30 ans d'expérience dans l'industrie des sciences de la vie.
Ce tour de financement, dirigé par Sonder Capital avec la participation d'investisseurs stratégiques, soutiendra l'essai crucial à venir et le développement d'applications cliniques supplémentaires. La technologie de Jupiter répond aux limitations des thérapies basées sur cathéter en offrant stabilité et contrôle au sein d'anatomies cardiovasculaires complexes, révolutionnant potentiellement le traitement de millions de patients dans le monde entier.
Jupiter Endovascular, ein Medizintechnologie-Startup, hat den Stealth-Modus verlassen und 21 Millionen Dollar an neuer Finanzierung erhalten, um eine entscheidende Studie zur Lungenembolie zu finanzieren. Das Unternehmen entwickelt eine neue Klasse von endovaskulären Verfahren mit Endoportal Control™ Technologie, die darauf abzielt, die Präzision des direkten chirurgischen Zugangs für katheterbasierte Interventionen zu nutzen. Carl J. St. Bernard wurde zum CEO ernannt und bringt mehr als 30 Jahre Erfahrung in der Biowissenschaftsbranche mit.
Die Finanzierungsrunde, angeführt von Sonder Capital mit der Beteiligung strategischer Investoren, wird die bevorstehende entscheidende Studie und die Entwicklung zusätzlicher klinischer Anwendungen unterstützen. Die Technologie von Jupiter adressiert die Einschränkungen katheterbasierter Therapien, indem sie Stabilität und Kontrolle innerhalb komplexer kardiovaskulärer Anatomien bietet und potenziell die Behandlung für Millionen von Patienten weltweit revolutionieren könnte.
- $21 million in new financing secured
- Appointment of experienced CEO Carl J. St. Bernard
- Development of novel Endoportal Control™ technology
- Potential to address unmet clinical needs in complex cardiovascular anatomies
- Support from strategic investors and Sonder Capital
- None.
Insights
Jupiter Endovascular's $21 million financing marks a significant milestone in the development of their Endoportal Control™ technology. This innovative approach aims to overcome longstanding limitations in catheter-based therapies by providing surgical-like precision in a minimally invasive format. The focus on pulmonary embolism treatment addresses a critical unmet need in complex cardiovascular interventions.
The technology's potential to revolutionize endovascular procedures could lead to improved patient outcomes and expanded treatment options. However, the success of the upcoming pivotal trial will be important in determining the clinical viability and market potential of this approach. Investors should closely monitor the trial results, as positive outcomes could position Jupiter Endovascular as a disruptive force in the
The
The appointment of Carl J. St. Bernard as CEO brings valuable industry experience and leadership to guide the company through its clinical and commercial phases. His background with major players like Johnson & Johnson and GE Healthcare could prove instrumental in navigating regulatory challenges and potential partnerships.
While the company's exit from stealth mode and substantial funding are positive indicators, investors should be aware that medical device startups face significant regulatory hurdles and often require substantial additional capital before reaching profitability.
Carl J. St. Bernard Appointed as Chief Executive Officer
“For decades, the field of catheter-based therapies has been limited by the technological constraints of catheters that lose stability and control within the anatomy,” said Kate Garrett, Managing Partner at Sonder Capital. “Jupiter Endovascular has developed a revolutionary approach with the potential to overcome these constraints by providing clinicians the precision and control of a surgical approach while maintaining the minimally invasive profile of an endovascular procedure. This novel approach may address a significant unmet clinical need in patients with disease residing in complex cardiovascular anatomies, such as the pulmonary arteries.”
The company has appointed Carl J. St. Bernard as Jupiter Endovascular’s Chief Executive Officer. St. Bernard, an industry veteran with a wealth of medical technology leadership experience, joins Jupiter from Alta Biomaterials, where he held the role of President and CEO. He has over 30 years of experience in the life sciences arena and has held senior executive positions at CeloNova BioSciences, Tryton Medical, Johnson & Johnson Vision, LifeCell, Cordis, and GE Healthcare. He is also an AdvaMed board director.
“I am very excited to join the Jupiter Endovascular team. The Endoportal ControlTM technology, which leverages Jupiter’s unique and exclusive intellectual property to create a catheter-based device that flexibly navigates through a patient’s vasculature before fixing into a stable position, is designed to give interventionalists the confidence and support they need to deliver a prescribed cardiovascular therapy. This represents a generational advance in technology with the potential to revolutionize the treatment of millions of patients worldwide,” said St. Bernard. “We are thrilled to partner with Sonder Capital and our other highly valued investors as we bring this innovation to the clinic and create the foundation for our entry into the Pulmonary Embolism market and future clinical areas where we see a compelling opportunity for Endoportal ControlTM to improve the lives and well-being of patients.”
"We are excited to welcome Carl St. Bernard as the CEO of Jupiter Endovascular,” said Jay
About Jupiter Endovascular
Jupiter Endovascular is a medical technology startup developing the endoportal procedure, a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions. The procedure uses an endoportal device that navigates flexibly through the vasculature via percutaneous access. Once in position, the endoportal device can be fixed into a stable state to deliver an interventional treatment with surgical-like precision and control from an endovascular access point. To learn more about Jupiter Endovascular, visit www.jupiterendo.com.
About Sonder Capital
Sonder’s team of veteran investors, innovators, founder-operators, and company builders is known not only for their individual achievements, but also for their collective success in creating, funding, and leading private and public companies that have transformed healthcare for millions of patients globally — including Intuitive Surgical (NASDAQ:ISRG), Procept Biorobotics (NASDAQ:PRCT), Shockwave Medical, Auris Health, and Reflexion Medical, among others. Sonder’s extensive network of limited partners is global and includes industry leaders, high-net-worth individuals, and leading family offices focused on investing in game-changing healthcare technologies. Sonder Capital was co-founded in 2019 by healthcare luminaries Jay Watkins and Fred Moll, M.D.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240815995561/en/
Michelle McAdam, Chronic Communications, Inc.
michelle@chronic-comm.com
(310) 902-1274
Source: Jupiter Endovascular, Inc.
FAQ
What is Jupiter Endovascular's new financing amount and its purpose?
Who was appointed as the new CEO of Jupiter Endovascular?
What is the main technology Jupiter Endovascular is developing?
Who led the funding round for Jupiter Endovascular?
